Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, 52-Week Phase II Study to Evaluate the Efficacy of Intravenous RO7046015/Prasinezumab (PRX002) in Participants With Early Parkinson's Disease With a 6-Year All-Participants-on-Treatment Extension
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 22 Mar 2024
Price :
$35
*
At a glance
- Drugs Prasinezumab (Primary)
- Indications Parkinson's disease
- Focus Proof of concept; Therapeutic Use
- Acronyms PASADENA
- Sponsors Roche
- 27 Apr 2023 Results of PASADENA Part 2 at Week 104 and Part 3 Week 52 open-label extension , presented at the 75th Annual Meeting of the American Academy of Neurology 2023
- 27 Apr 2023 Results of pooled post hoc analysis assessing utility of plasma neurofilament light chain (pNfL) as a biomarker of neurodegenerative diseases using a fixed threshold for screening in clinical practice from (NCT03664804, NCT03664804, NCT03100149, NCT01194570) presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
- 31 Mar 2023 According to a Prothena Corporation media release, data from this study presented at the AD/PD 2023 Meeting